draflazine

a nucleoside transport inhibitor; has cardioprotective effect; draflazine is the (-)-enantiomer; R 88016 is the (+)-enantiomer

Also Known As:

2-aminocarbonyl-N-(4-amino-2,6-dichlorophenyl)-4-(5,5-bis(4-fluorophenyl)-pentyl)-1-piperazineacetamide; R 75 231; R 75231; R 88 016; R 88016; R-75231; R-88016; R75231; 1-Piperazineacetamide, 2-(aminocarbonyl)-N-(4-amino-2,6-dichlorophenyl)-4-(5,5-bis(4-fluorophenyl)pentyl)-

Networked: 18 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperazines: 26
    - draflazine: 18

Experts

1.	Fukuda, Ayumu: 1 article (01/2014)
2.	Kamigaki, Masayo: 1 article (01/2014)
3.	Nishiya, Yoichi: 1 article (01/2014)
4.	Sakuma, Takashi: 1 article (01/2014)
5.	Sasho, Setsuya: 1 article (01/2014)
6.	Sato, Hidetaka: 1 article (01/2014)
7.	Seishi, Takashi: 1 article (01/2014)
8.	Sekine, Susumu: 1 article (01/2014)
9.	Shibata, Kenji: 1 article (01/2014)
10.	Shimizu, Yukiko: 1 article (01/2014)

Related Diseases

1.	Ischemia 01/27/1997 - "R75231 was given to the animals by continuous intravenous infusion for 30 min before ischemia at a dose of 0.1 mg/kg (Group 2, n=6), 0.05 mg/kg (Group 3, n=6), or 0.025 mg/kg (Group 4, n=6). " 11/04/1997 - "Tissue adenosine at the end of ischemia was elevated by draflazine compared with saline-treated hearts: after low-flow ischemia to 0.10+/-0.05 versus 0.00+/-0.00 micromol x g(-1) dry wt (P<.05) and after zero-flow ischemia to 1.73+/-0.82 versus 0.15+/-0.03 micromol x g(-1) dry wt (P<.05). " 01/01/1994 - "R 75231 increased time to contracture during global ischemia in a concentration-dependent manner (EC25 = 2.6 microM) that was comparable to the structurally related compound lidoflazine (EC25 = 1.2 microM). " 11/01/1994 - "In other groups of rabbits, PC was conducted with 2-min ischemia and 5-min reperfusion with or without injection of the nucleoside transport inhibitor (0.34 or 0.10 mg/kg dilazep or 0.05 mg/kg of R75231) before PC. " 12/01/1991 - "Before ischemia either solvent (group 1), 5 mumol/L of adenosine (group 2), or 0.64 mg/L R75231 (group 3) was added to the perfusate. "
2.	Infarction (Infarctions) 04/01/1997 - "Infarct size reduction with the nucleoside transport inhibitor R-75231 in swine." 01/01/1996 - "In a randomised, double-blind, placebo controlled study, we evaluated the tolerability and safety of draflazine, a nucleoside transport inhibitor, in the treatment of patients with unstable angina and non-Q-wave infarction. "
3.	Unstable Angina 01/01/1996 - "In a randomised, double-blind, placebo controlled study, we evaluated the tolerability and safety of draflazine, a nucleoside transport inhibitor, in the treatment of patients with unstable angina and non-Q-wave infarction. "
4.	Contracture 01/01/1993 - "The mean time to onset and extent of contracture during ischaemia was similar in R75231 treated and control groups, at 42(4) v 41(4) min and 27(3) v 26(6) mm Hg, respectively. " 01/01/1994 - "R 75231 increased time to contracture during global ischemia in a concentration-dependent manner (EC25 = 2.6 microM) that was comparable to the structurally related compound lidoflazine (EC25 = 1.2 microM). "
5.	Ischemic Contracture 11/04/1997 - "In the zero-flow protocol, draflazine also significantly reduced ischemic contracture and release of creatine kinase. "

Related Drugs and Biologics

1.	Nucleosides
2.	Renin
3.	Angiotensins
4.	Adenosine (Adenocard)
5.	Lidoflazine
6.	Dipyridamole (Persantine)
7.	Dilazep
8.	Hypoxanthine
9.	Dialysis Solutions
10.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)

Related Therapies and Procedures

1.	Intravenous Infusions